Viking Therapeutics Inc.
Developing “undervalued” assets for metabolic, endocrine disorders
This article was originally published in Start Up
Viking Therapeutics Inc. has clinical-stage compounds for disorders amplifying as the world's population ages. The start-up’s first drug candidate is a potential treatment for people recovering from hip fracture; the second shows promise for fatty liver disorders that are spreading as the western diet does.
You may also be interested in...
The company's oral non-steroidal SARM could be the first approved drug to help patients maintain muscle after hip fracture surgery, but will FDA seek pivotal data on muscle mass or on functional measures?
The mid-stage company is approaching Phase II data read outs for two lead assets. It is looking to partner with larger pharmas, but is also pursuing orphan indications that it could develop independently.
Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.